Drugs & Targets China’s National Medical Products Administration grants Breakthrough Therapy designation to olverembatinib for Ph+ ALL March 14, 2025Vol.51 No.10
Drugs & Targets FDA grants Orphan Drug designation to rhenium obisbemeda for leptomeningeal metastases in lung cancer March 14, 2025Vol.51 No.10
Drugs & Targets University of New England licenses cancer biomarker test to Satya Diagnostics March 07, 2025Vol.51 No.09
Drugs & Targets FDA accepts review for odronextamab BLA in r/r follicular lymphoma February 28, 2025Vol.51 No.08
Drugs & Targets Tempus AI, Stemline Therapeutics collaborate to enhance ESR1 testing in breast cancer February 28, 2025Vol.51 No.08
Drugs & Targets DeepHealth, TeraRecon announce collaboration around integrated AI and advanced visualization February 28, 2025Vol.51 No.08
Drugs & Targets FDA grants priority review to Boehringer’s BI 1810631 for the treatment of HER2-mutant advanced NSCLC February 21, 2025Vol.51 No.07
